Cylembio (imsapepimut and etimupepimut, adjuvanted), an off-the-shelf therapeutic cancer vaccine, plus pembrolizumab narrowly missed on its primary endpoint of progression free survival for patients with unresectable or metastatic melanoma, according to phase III trial results.
Getting NCI clinical trials to the community has never been an easy task. Has it been getting simpler or more difficult in recent years?
